会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • ORAL ENTERIC ANTIDEPRESSANT FORMULATION
    • 口服避孕药配方
    • US20120003303A1
    • 2012-01-05
    • US13143408
    • 2010-01-08
    • Barry Scott BrandJames Cecil FreeDaniel Joseph BurchMark Joseph Baric
    • Barry Scott BrandJames Cecil FreeDaniel Joseph BurchMark Joseph Baric
    • A61K31/39A61P9/12A61K9/14C07D327/08A61K9/48
    • A61K9/5078A61K9/2846A61K9/5026A61K9/5042
    • Pharmaceutical presentations of phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are protected from binding to active ingredient in the stomach. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: (I) wherein n is 0, 1 or 2; R1 is a branched or straight chain C1-5 alkyl or C3-6 cycloalkyl optionally substituted with hydroxyl, or one or more halogens; and X1, X2, X3, X4, and X5 are either all hydrogens or one or two of X1, X2, X3, X4, and X5 are halogen and the remainder are hydrogens, with the proviso that when n is 0 or 1 and each X is hydrogen, R1 is not methyl. A wide variety of enteric mechanisms may be utilized so as to provide release of the active ingredient essentially out of the environment of the stomach after ingestion as a pharmaceutical presentation, such as a tablet or capsule. Presentations include enteric coated tablets, enteric coated capsules, capsules containing enteric coated beads.
    • 公开了基于吩草素的MAO-A抑制剂的药物显示,由此保护MAO受体免受胃中的活性成分的结合。 特别的基于苯基硫蛋白的MAO-A抑制剂包括下式的那些:(I)其中n为0,1或2; R1是任选被羟基或一个或多个卤素取代的支链或直链C 1-5烷基或C 3-6环烷基; 且X 1,X 2,X 3,X 4和X 5均为氢,或者X 1,X 2,X 3,X 4和X 5中的一个或两个为卤素,其余为氢,条件是当n为0或1时, X是氢,R1不是甲基。 可以使用各种各样的肠溶机制,以便在摄取后作为药物呈递,例如片剂或胶囊,提供活性成分基本上脱离胃外的环境。 介绍包括肠溶包衣片剂,肠溶衣胶囊,含有肠溶包衣珠粒的胶囊。
    • 4. 发明申请
    • ORAL SUSTAINED RELEASE ANTIDEPRESSANT FORMULATION
    • 口服持续释放抗生素配方
    • US20120003274A1
    • 2012-01-05
    • US13143403
    • 2010-01-08
    • Barry Scott BrandJames Cecil Free
    • Barry Scott BrandJames Cecil Free
    • A61K9/00A61K31/39A61P25/24C07D327/08
    • C07D327/08
    • Pharmaceutical presentations or phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are capable of sustained release in the digestive tract. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: wherein n is 0, 1 or 2; R1 is a branched or straight chain C1-5 alkyl or C3-6 cycloalkyl optionally substituted with hydroxyl, or one or more halogens; and X1, X2, X3, X4, and X5 are either all hydrogens or one or two of X1, X2, X3, X4, and X5 are halogen and the remainder are hydrogens, with the proviso that when n is 0 or 1 and each X is hydrogen, R1 is not methyl. A wide variety or sustained release mechanisms can be utilized so as to provide gradual release of the active ingredient after ingestion as a pharmaceutical presentation, such as a tablet or capsule. Presentations include sustained release tablets, sustained release capsules, capsules containing sustained release beads.
    • 公开了药物表现或基于phenoxathiin的MAO-A抑制剂,由此MAO受体能够在消化道中持续释放。 特别的基于苯基硫蛋白的MAO-A抑制剂包括下式的那些:其中n为0,1或2; R1是任选被羟基或一个或多个卤素取代的支链或直链C 1-5烷基或C 3-6环烷基; 且X 1,X 2,X 3,X 4和X 5均为氢,或者X 1,X 2,X 3,X 4和X 5中的一个或两个为卤素,其余为氢,条件是当n为0或1时, X是氢,R1不是甲基。 可以使用多种或持续释放机制,以便在摄取后作为药物呈递(例如片剂或胶囊)逐渐释放活性成分。 呈现包括持续释放片剂,缓释胶囊,含缓释珠粒的胶囊。